Vitamin D is a particularly important sterol hormone and its effects beyond bone are increasingly recognized. Over the last decade clinical interest has grown in vitamin D, with increased recognition of deficiency and hence increased prescribing of vitamin D products. However, the increased prescription of vitamin D has generally been met with unlicensed vitamin D products which potentially expose the patient to clinical risk. This review discusses the issues relating to the clinical use of unlicensed vitamin D products, safety concerns that may arise from this, as well as discussing the medico-legal responsibilities of the prescriber and dispenser.
Vitamin D: quality and safetyThere has been a considerable increase in interest surrounding vitamin D over the last decade with the number of publications relating to vitamin D having risen by more than 250% over the last decade (Figure 1). This research may have been stimulated by the re-emergence of diseases such as rickets and osteomalacia, a high prevalence of deficiency together with a greater appreciation of the ubiquitous presence of the vitamin D receptor and potential role beyond regulation of calcium and bone. As such, vitamin D deficiency is implicated in increased risk of fractures, falls and mortality [1,2]. Treatment with vitamin D appears to reduce risk of falls [3], fractures [4] and, potentially, mortality [5]. In consequence, the Chief Medical Officers of the United Kingdom have recommended treatment with vitamin D for at risk groups, particularly the young, pregnant and the elderly [6].Accompanying this increased research interest, there has also been a considerable rise in the number of prescriptions of vitamin D in the UK over the last decade. Since 2008, vitamin D monotherapy in primary care in England has increased more 8000% in prescription numbers and 5000% in cost (Figure 2) [7]. These data reveal that currently, 190 000 prescriptions for vitamin D are issued each month at a net ingredient cost of £2.22 million, with cholecalciferol accounting for 98% and 93% of volume and cost, respectively. However, of these prescriptions, the majority (59%) relate to the use of unlicensed treatments.